SCHEMBL6963205

SCHEMBL6963205

O=c1oc(-c2ccccc2)cc(O)c1C(Sc1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
POLB P06746 1/20 0.47
PTGES O14684 1/20 0.42
PPARG P37231 2/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
ABCB1 P08183 4/20 0.41
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPT P10636 6/20 0.39
FTO Q9C0B1 5/20 0.39
ALOX15 P16050 4/20 0.39
ALDH1A1 P00352 4/20 0.39
CYP3A4 P08684 4/20 0.39
KDM4E B2RXH2 4/20 0.39
TP53 P04637 4/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6954902 0.89 PTGES (0.44) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL6954921 0.88 PTGES (0.43) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL6959208 0.82 ALDH1A1 (0.44) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL9038373 0.82 SMN1; SMN2 (0.45) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL6955768 0.81 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL9038370 0.80 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL7367968 0.79 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL6953348 0.78 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL6956690 0.78 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL1POLBPTGESPPARG
SCHEMBL6964293 0.77 SMN1; SMN2 (0.42) SMN1; SMN2L3MBTL1POLBPTGESPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP claimed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed